secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001689548-26-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Praxis promotes Sniecinski to COO; adds Kindler and Arbuckle to board
---------------------------------------------------------------------

- Megan Sniecinski promoted to COO effective Jan 1, 2026; previously CBO since Dec 2021.
- Sniecinski's base salary increased to $626,000, target bonus 50% of salary for 2026.
- Jeffrey B. Kindler elected to Board as Class II director, effective Jan 8, 2026; deemed independent.
- Stuart A. Arbuckle elected to Board as Class II director, effective Jan 8, 2026; deemed independent.
- Kindler and Arbuckle entitled to initial stock option awards and annual retainers per company policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000005/0001689548-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000005/prax-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer